North Carolina is known throughout the world for its outstanding healthcare.
Hospitals and clinics deliver nationally ranked healthcare. Meanwhile, research labs and biomanufacturing plants yield new therapies, vaccines, diagnostics and other medical innovations across the state. These capabilities contribute to the state's global life science leadership.
Huge global pharmaceutical companies are drawn to North Carolina for many reasons. One of the biggest is our highly educated and uniquely skilled workforce. Here you'll find the Spanish company Grifols making therapeutic proteins to treat rare diseases including immune deficiencies and genetic emphysema. Danish multinational Novo Nordisk produces insulin and other treatments for diabetes. Massachusetts-based Biogen delivers its multiple sclerosis medicines from its sprawling RTP facility. Access to all human therapeutics companies in North Carolina can be found on the Company Directory.
Adding to North Carolina's rich life science environment, our prestigious research universities every year spawn exciting new entrepreneurial ventures, many with NCBiotech funding support. This infusion, bolstered by a steady influx of companies recruited from around the world, provides a constant energy that feeds into North Carolina's global life science leadership.
G1 Therapeutics, for example, is a spin-out from the University of North Carolina at Chapel Hill. After a successful IPO, it is now a public company developing novel therapies that address significant unmet needs in people with various cancers. And Precision BioSciences, a 2006 Duke University spin-out with a unique method to target and alter DNA, is making headlines with its own anti-cancer developments.
Vaccines, too, are being developed against a wide variety of diseases in North Carolina, including seasonal and pandemic flu, cancer, rabies and malaria. For example, Seqirus owns a billion-dollar biomanufacturing plant that produces the nation's first influenza vaccines using cells to avoid delays and problems associated with the traditional process of growing the vaccine components in poultry eggs. Similarly, Medicago is using genetically altered plants to produce novel flu vaccines and therapeutic proteins.
Physician researchers at the Wake Forest Institute for Regenerative Medicine, with grant help from NCBiotech, are making enormous headway adapting animal organs for human use and growing human organs from donors’ own cells.
The breadth and scope of human health innovation across North Carolina is awe-inspiring.
And the benefits continue to accrue in new ways. Two examples:
The Triangle Global Health Consortium is a group of academic, governmental, business and nonprofit organizations working together to establish North Carolina as an international center for research, training, education, advocacy and business development dedicated to improving the health of the world’s communities.
The North Carolina Precision Health Collaborative is a community of companies, universities and nonprofit organizations dedicated to developing the state’s full scientific, medical and economic potential in data-driven health care targeted to the individual patient.